Innovation Pharmaceuticals Inc (IPIX)

[58nout]

From the September 9th PR:

Regarding Kevetrin, Cellceutix’s lead anti-cancer compound in a dose escalation Phase 1 clinical trial, no drug-related serious adverse events or significant laboratory changes were reported in the eighth cohort in which patients were treated with 215 mg/m2 of Kevetrin. The safety committee yesterday determined that the next 9th cohort may be treated with 350 mg/m2. Patient dosing is scheduled to begin this week.

Unless there was an unforeseen delay, this level of dosing is underway and we have heard nothing. I like hearing nothing on this, who wouldn't?

GO CTIX